Arcellx, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
February 28, 2024 at 04:05 pm EST
Share
Arcellx, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 70.69 million compared to USD 188.68 million a year ago. Basic loss per share from continuing operations was USD 1.47 compared to USD 5.19 a year ago.
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Companyâs lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).